VA CT Healthcare Systems
Welcome,         Profile    Billing    Logout  
 3 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Petrakis, Ismene
VA-BRAVE, NCT04375033: A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

Recruiting
4
952
US
Sublingual buprenorphine with naloxone, Injectable subcutaneous buprenorphine
VA Office of Research and Development
Opioid Use Disorder
09/28
05/29
NCT03852628: Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD

Terminated
2
69
US
2mg Buprenex and 380mg Vivitrol, 2mg Buprenex (SL, qd) and 380mg Vivitrol (IM, q4weeks), 2mg BUP/NLTRX, Placebo (SL pill qd, IM injection q4weeks), Placebo
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, United States Department of Defense, RTI International
Post Traumatic Stress Disorder, Alcohol Abuse
05/22
01/23
NCT03605342: Optimal Treatment of Veterans With PTSD and Comorbid OUD

Terminated
2
38
US
Buprenorphine, Cognitive Processing Therapy (CPT), Individual Drug Counseling (IDC)
VA Office of Research and Development
Post-Traumatic Stress Disorders, Opiate Use Disorder
04/23
04/23
NCT04827056: Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study

Completed
1
10
US
Placebo, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, BXCL501 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg, BXCL501 80µg, Ethanol Infusion, PTSD Reactivity Condition, Alcohol Cue Reactivity
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, United States Department of Defense, Congressionally Directed Medical Research Programs, RTI International, VA Connecticut Healthcare System, BioXcel Therapeutics Inc, Yale University
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
05/23
06/23
NCT06335407: Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study

Not yet recruiting
1
10
US
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, BXCL501 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg, BXCL501 80µg
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, United States Department of Defense, Congressionally Directed Medical Research Programs, VA Connecticut Healthcare System, BioXcel Therapeutics Inc, Yale University, RTI International
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
09/25
10/25
NCT05948605: EMPOWER AUD Pivotal Trial

Active, not recruiting
N/A
128
US
Empower Neuromodulation System
Theranova, L.L.C.
Alcoholism, Alcohol Abuse, Alcohol Use Disorder
03/25
05/25
Ralevski, Elizabeth
VA-BRAVE, NCT04375033: A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

Recruiting
4
952
US
Sublingual buprenorphine with naloxone, Injectable subcutaneous buprenorphine
VA Office of Research and Development
Opioid Use Disorder
09/28
05/29
NCT02187198: Buprenorphine Treatment for Opioid Dependence

Completed
3
9
US
Buprenorphine, Naloxone, Suboxone, Buprenex, Subutex
Yale University, United States Department of Defense
Opioid Dependence
02/22
01/23
NCT04015869: Effect of Allopregnanolone on Stress-induced Craving

Completed
1
16
US
Allopregnanolone, Placebos
Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder
09/23
09/23
Kozal, Michael J
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Petrakis, Ismene
VA-BRAVE, NCT04375033: A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

Recruiting
4
952
US
Sublingual buprenorphine with naloxone, Injectable subcutaneous buprenorphine
VA Office of Research and Development
Opioid Use Disorder
09/28
05/29
NCT03852628: Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD

Terminated
2
69
US
2mg Buprenex and 380mg Vivitrol, 2mg Buprenex (SL, qd) and 380mg Vivitrol (IM, q4weeks), 2mg BUP/NLTRX, Placebo (SL pill qd, IM injection q4weeks), Placebo
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, United States Department of Defense, RTI International
Post Traumatic Stress Disorder, Alcohol Abuse
05/22
01/23
NCT03605342: Optimal Treatment of Veterans With PTSD and Comorbid OUD

Terminated
2
38
US
Buprenorphine, Cognitive Processing Therapy (CPT), Individual Drug Counseling (IDC)
VA Office of Research and Development
Post-Traumatic Stress Disorders, Opiate Use Disorder
04/23
04/23
NCT04827056: Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study

Completed
1
10
US
Placebo, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, BXCL501 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg, BXCL501 80µg, Ethanol Infusion, PTSD Reactivity Condition, Alcohol Cue Reactivity
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, United States Department of Defense, Congressionally Directed Medical Research Programs, RTI International, VA Connecticut Healthcare System, BioXcel Therapeutics Inc, Yale University
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
05/23
06/23
NCT06335407: Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study

Not yet recruiting
1
10
US
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, BXCL501 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg, BXCL501 80µg
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, United States Department of Defense, Congressionally Directed Medical Research Programs, VA Connecticut Healthcare System, BioXcel Therapeutics Inc, Yale University, RTI International
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
09/25
10/25
NCT05948605: EMPOWER AUD Pivotal Trial

Active, not recruiting
N/A
128
US
Empower Neuromodulation System
Theranova, L.L.C.
Alcoholism, Alcohol Abuse, Alcohol Use Disorder
03/25
05/25
Ralevski, Elizabeth
VA-BRAVE, NCT04375033: A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

Recruiting
4
952
US
Sublingual buprenorphine with naloxone, Injectable subcutaneous buprenorphine
VA Office of Research and Development
Opioid Use Disorder
09/28
05/29
NCT02187198: Buprenorphine Treatment for Opioid Dependence

Completed
3
9
US
Buprenorphine, Naloxone, Suboxone, Buprenex, Subutex
Yale University, United States Department of Defense
Opioid Dependence
02/22
01/23
NCT04015869: Effect of Allopregnanolone on Stress-induced Craving

Completed
1
16
US
Allopregnanolone, Placebos
Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder
09/23
09/23
Kozal, Michael J
No trials found

Download Options